NASDAQ:IOSP - Innospec Stock Price, Forecast & News

Innospec trades on the NASDAQ under the ticker symbol "IOSP."

Innospec announced a Semi-Annual dividend on Tuesday, November 5th. Investors of record on Tuesday, November 19th will be paid a dividend of $0.52 per share on Wednesday, November 27th. The ex-dividend date is Monday, November 18th. This is an increase from Innospec's previous Semi-Annual dividend of $0.50. View Innospec's Dividend History.

Innospec Inc. (NASDAQ:IOSP) issued its earnings results on Tuesday, November, 5th. The specialty chemicals company reported $1.40 earnings per share for the quarter, topping analysts' consensus estimates of $1.25 by $0.15. The specialty chemicals company earned $371.90 million during the quarter, compared to the consensus estimate of $367.65 million. Innospec had a net margin of 6.69% and a return on equity of 15.52%. The firm's revenue for the quarter was up 2.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.20 EPS. View Innospec's Earnings History.

Innospec is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Innospec.

1 Wall Street analysts have issued twelve-month price objectives for Innospec's shares. Their forecasts range from $95.00 to $95.00. On average, they expect Innospec's stock price to reach $95.00 in the next year. This suggests that the stock has a possible downside of 9.1%. View Analyst Price Targets for Innospec.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innospec in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innospec.

Media coverage about IOSP stock has been trending neutral on Tuesday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Innospec earned a news sentiment score of 0.3 on InfoTrie's scale. They also assigned news coverage about the specialty chemicals company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the next several days. View News Stories for Innospec.

Innospec saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 391,900 shares, an increase of 6.7% from the January 15th total of 367,400 shares. Based on an average daily volume of 98,700 shares, the short-interest ratio is presently 4.0 days. Currently, 1.6% of the company's stock are sold short. View Innospec's Current Options Chain.

Some companies that are related to Innospec include Ecolab (ECL), Sherwin-Williams (SHW), International Flavors & Fragrances (IFF), Celanese (CE), RPM International (RPM), Albemarle (ALB), Ashland Global (ASH), NewMarket (NEU), W. R. Grace & Co (GRA), Balchem (BCPC), Quaker Chemical (KWR), HB Fuller (FUL), PolyOne (POL), Sensient Technologies (SXT) and Stepan (SCL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Innospec investors own include Intellia Therapeutics (NTLA), Las Vegas Sands (LVS), Altria Group (MO), Exxon Mobil (XOM), NVIDIA (NVDA), Franklin Resources (BEN), Colgate-Palmolive (CL), Eastman Chemical (EMN), Emerson Electric (EMR) and Invesco (IVZ).

Innospec's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (11.72%), State Street Corp (2.90%), Champlain Investment Partners LLC (2.71%), Royce & Associates LP (2.42%), Bank of New York Mellon Corp (1.25%) and Westwood Holdings Group Inc. (1.24%). Company insiders that own Innospec stock include Brian Watt, Catherine Hessner, David Earl Williams, Hugh Aldous, Ian Cleminson, Ian Malcolm Mcrobbie, Milton C Blackmore, Patrick Williams, Philip Curran and Philip John Boon. View Institutional Ownership Trends for Innospec.

IOSP stock was sold by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., First Wilshire Securities Management Inc., NWQ Investment Management Company LLC, Bank of New York Mellon Corp, Royce & Associates LP, Westwood Holdings Group Inc. and SG Americas Securities LLC. Company insiders that have sold Innospec company stock in the last year include Brian Watt, Catherine Hessner, Hugh Aldous, Ian Cleminson, Milton C Blackmore, Patrick Williams, Philip Curran and Philip John Boon. View Insider Buying and Selling for Innospec.

IOSP stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, James Investment Research Inc., Thrivent Financial for Lutherans, Great West Life Assurance Co. Can, Bank of Montreal Can, Citigroup Inc., Mackay Shields LLC and First Trust Advisors LP. View Insider Buying and Selling for Innospec.

Shares of IOSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IOSP stock can currently be purchased for approximately $104.51.

Innospec has a market capitalization of $2.56 billion and generates $1.48 billion in revenue each year. Innospec employs 2,000 workers across the globe.View Additional Information About Innospec.

The official website for Innospec is http://www.innospecinc.com/.

Innospec's mailing address is 8310 SOUTH VALLEY HIGHWAY SUITE 350, ENGLEWOOD CO, 80112. The specialty chemicals company can be reached via phone at 303-792-5554 or via email at [email protected]